| INTRODUC TI ON
Expression of the epidermal growth factor receptor (EGFR) influences the malignant behavior of many types of cancer cells in manners dependent on or independent of the kinase activity of the receptor. 1, 2 Amplification of the EGFR gene is the most common genetic alteration in malignant gliomas, with EGFR overexpression having been associated with increased tumor invasion and chemoresistance. [3] [4] [5] Infiltration of tumor cells into brain tissue is a pathological hallmark of malignant gliomas and is enhanced by autocrine and paracrine factors, including chemokines and growth factors such as epidermal growth factor (EGF). 6 Extracellular glutamate released from glioma cells has also been shown to act as an autocrine factor that promotes malignant behavior in these cells. 7, 8 Malignant gliomas that release glutamate often manifest an invasive growth pattern that is characterized by the induction of an inflammatory response in the surrounding tissue that results in neuronal death and tumor expansion. 9 System xc(-) comprises xCT and CD98hc subunits and is a major plasma membrane antiporter responsible for the cellular uptake of cystine in exchange for intracellular glutamate. 10 We previously showed that the intracellular domain of EGFR interacts with and thereby promotes the surface expression of xCT in glioma cells in a manner independent of receptor kinase activity, resulting in increased cystine uptake and glutamate release. 8 The released glutamate then acts as an autocrine factor to enhance glioma progression through interaction with glutamate receptors at the cell surface. 11, 12 Glutamate receptors include both ionotropic and metabotropic receptors and mediate excitatory neurotransmission. 13 Glutamate released from malignant gliomas can achieve excitotoxic levels and promote tumor cell proliferation and migration through activation of ionotropic receptors. 9, 14 Ionotropic glutamate receptors are ligandgated ion channels that are activated by glutamate and comprise α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR), kainate receptor, delta receptor and N-methyl-d-aspartate receptor (NMDAR) subtypes. 13 
| MATERIAL S AND ME THODS

| Cell culture
The human glioma cell lines T98G and U87MG were obtained from the ATCC (Manassas, VA, USA). U87MG cells stably expressing human EGFR (U87MG-E cells) were kindly provided by M. Nagane (Kyorin University Faculty of Medicine, Tokyo, Japan). 18 All cells were maintained under 5% CO 2 at 37°C in DMEM containing glucose at 4.5 g/L (Nacalai, Kyoto, Japan) and supplemented with 10% FBS.
| Reagents
Recombinant human EGF was obtained from PeproTech (Rocky Hill, NJ, USA), gefitinib was from Tocris Bioscience (Minneapolis, MN, USA), and sulfasalazine, MK-801, GYKI-52466 and glutamate were from Sigma-Aldrich (St. Louis, MO, USA). Flow cytometry was performed with a FACSCalibur instrument (BD Biosciences, Tokyo, Japan).
| Flow cytometric analysis
| Assay of glutamate
Parental U87MG (U87MG-P) or U87MG-E cells were transferred to 6-well plates (1 × 10 6 cells per well), cultured for 12 hours, washed with PBS, and cultured for an additional 8 hours in 2 mL of glutamate-free medium (DMEM with glucose at 4.5 g/L; Nacalai) in the absence or presence of sulfasalazine (400 μmol/L).
The amount of glutamate released into culture supernatants was then measured with the use of a fluorometric glutamate assay kit (Abcam, Tokyo, Japan).
| In vitro chemotaxis assay
U87MG-P or U87MG-E cells were suspended in serum-free DMEM containing glucose at 4. were isolated by centrifugation and washed 3 times with RIPA buffer, after which the bead-bound proteins were subjected to immunoblot analysis.
| Immunoprecipitation analysis
| Immunofluorescence analysis
U87MG-E cells were fixed with 4% paraformaldehyde and incubated 
| Growth of subcutaneous tumors and drug treatment in vivo
U87MG-E cells (2 × 10 6 ) were implanted subcutaneously in the flank of nude mice. The mice were injected intraperitoneally with physiological saline, sulfasalazine (250 mg/kg), MK-801 (1 mg/kg) or both drugs once a day for 18 days beginning 3 days after cell injection. All animal experiments were performed in accordance with protocols approved by the Ethics Committee of Keio University.
| Quantitative RT-PCR analysis
Total RNA was extracted from cells with the use of an RNeasy Mini Kit (Qiagen, Tokyo, Japan) and was subjected to RT with a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Quantitative PCR analysis was performed with the use of a Thermal Cycler Dice
Real Time System (Takara Bio, Otsu, Japan). The amplification protocol comprised an initial incubation at 95°C for 2 minutes and 40 cycles of incubation at 95°C for 30 seconds and 60°C for 30 seconds, and was followed by dissociation-curve analysis to confirm specificity. The analysis was performed with human primer sets (forward and reverse, respectively) for xCT (5′-CAGGAGAAAGTGCAGCTGAA-3′
and 5′-CTCCAATGATGGTGCCAATG-3′) and GluN2B (5′-TTCCGT AATGCTCAACATCATGG-3′ and 5′-TGCTGCGGATCTTGTTTACA AA-3′). Data were normalized by the abundance of GAPDH mRNA. 
| Orthotopic glioma model
| Statistical analysis
Quantitative data are presented as means ± SEM and were compared between 2 groups with the 2-tailed unpaired Student's t test or among 3 or more groups by one-way ANOVA followed by Tukey's post hoc test. Survival differences were statistically assessed by the Kaplan-Meier method and log-rank test. A P-value < .05 was considered statistically significant. Statistical analysis and graph construction were performed with GraphPad Prism software (San Diego, CA, USA).
| RE SULTS
| xCT-mediated glutamate release promotes glioma cell migration via N-methyl-d-aspartatesensitive glutamate receptor signaling
To examine the possible role of glutamate release through system xc(-) in EGF-elicited glioma cell migration, we studied U87MG glioma cells stably expressing EGFR (U87MG-E cells) and parental U87MG
(U87MG-P) cells. 8, 20 Consistent with our previous results, 8 ] i on the basis of Fluo-4 fluorescence intensity in U87MG-P or U87MG-E cells exposed (or not) to 250 μmol/L MK-801 or 2 μmol/L gefitinib for 10 minutes. Data in (B) to (F) are expressed relative to the corresponding control and are means ± SEM of 3 independent experiments. *P < .05, **P < .01, ***P < .001, ****P < .0001; NS, not significant (2-tailed Student's t test [B] or 1-way ANOVA followed by Tukey's post hoc test [C-F]). ROS, reactive oxygen species is activated in the EGFR-overexpressing glioma cells. To examine whether EGFR kinase activity affects such NMDAR-Ca 2+ signaling, we treated U87MG-E cells with the EGFR kinase inhibitor gefitinib.
Gefitinib significantly reduced [Ca
2+
] i in U87MG-E cells, although this effect was less pronounced than that of MK-801 ( Figure 1F ).
These results thus suggested that NMDAR-Ca 2+ signaling is regulated not only by extracellular glutamate but also by EGFR kinase activity in EGFR-overexpressing glioma cells.
| Epidermal growth factor receptor activation results in tyrosine phosphorylation of the Nmethyl-d-aspartate-sensitive glutamate receptor subunit GluN2B
Given that the expression of the GluN2B subunit of NMDAR has been associated with malignancy of multiple types of cancer, including glioma, 23 we examined whether GluN2B plays a role in EGF-dependent glioma cell migration. The shRNA-mediated knockdown of GluN2B was found to significantly attenuate EGF-elicited chemotaxis of U87MG-E cells (Figure 2A ), suggesting that EGFR kinase activity might modulate GluN2B function during EGF-dependent glioma cell migration.
Given that tyrosine phosphorylation of the COOH-terminal domain of GluN2B increases receptor activity, 23, 24 we next examined whether EGFR signaling might affect this phosphorylation event. EGF stimulation markedly increased the phosphorylation of GluN2B on Tyr 1474 as well as that of EGFR in U87MG-E cells but not in U87MG-P cells ( Figure 2B ), suggesting that EGF induced activation of both EGFR and GluN2B selectively in U87MG-E cells.
Furthermore, the EGF-induced tyrosine phosphorylation of GluN2B in U87MG-E cells as well as in T98G glioma cells, which express endogenous EGFR and xCT at high levels, was completely suppressed in the presence of gefitinib ( Figure 2C ), indicating that EGFR kinase activity is required for the EGF-induced tyrosine phosphorylation of GluN2B in EGFR-overexpressing glioma cells.
We also examined whether NMDAR signaling affects EGFR signaling in these glioma cells. Treatment with the NMDAR inhibitor MK-801 had no effect on the EGF-induced phosphorylation of EGFR or that of the major downstream signaling molecules ERK and AKT in U87MG-E or T98G cells ( Figure 2D ), suggesting that EGFR signaling is independent of NMDAR activity in these cells.
| Epidermal growth factor receptor interacts with and phosphorylates GluN2B
To provide insight into the molecular mechanism underlying EGFinduced GluN2B activation, we next examined whether GluN2B interacts with EGFR. Immunofluorescence analysis revealed the colocalization of EGFR and tyrosine-phosphorylated GluN2B in U87MG-E cells ( Figure 3A) . Furthermore, immunoprecipitation analysis revealed that EGFR interacts with GluN2B in U87MG-E and T98G cells, and To further examine whether xCT and NMDAR, indeed, are potential therapeutic targets for glioma in the brain microenvironment, we performed RNAi-mediated depletion of xCT, GluN2B, or both proteins in U87MG-E cells and evaluated the survival of mice with orthotopic tumors formed by these cells ( Figure 4B ). Stable depletion of xCT or GluN2B prolonged survival compared with that observed in mice implanted with control U87MG-E cells, and combined knockdown of both proteins resulted in a further extension of survival ( Figure 4C ). In contrast, the cell proliferation rate of U87MG-E cells in vitro was not affected by the stable depletion of xCT or GluN2B (data not shown).
F I G U R E 3
Epidermal growth factor receptor (EGFR) interacts with and phosphorylates GluN2B in glioma cells. A, Immunofluorescence analysis of EGFR (red) and tyrosine-phosphorylated GluN2B (pGluN2B, green) in U87MG-E cells that had been incubated in the presence of gefitinib (2 μmol/L) or DMSO vehicle for 2 hours. Nuclei were stained with Hoechst 33342 (blue). Scale bars, 20 μm. Arrowheads indicate colocalization of EGFR and phosphorylated GluN2B at the cell surface. B, U87MG-E or T98G cells that had been incubated in the absence or presence of epidermal growth factor (EGF) (20 ng/mL) or gefitinib (2 μmol/L) for 20 minutes were lysed and subjected to immunoprecipitation (IP) with antibodies to EGFR or with control IgG. The resulting precipitates, as well as the original cell lysates (Input), were subjected to immunoblot analysis with antibodies to phospho-GluN2B (Y1474), to GluN2B and to EGFR. C, GST fusion protein containing the catalytic domain of EGFR was assayed for kinase activity in vitro with GST or GST fusion proteins containing WT or Y1474F mutant forms of the COOH-terminal region of GluN2B. The reaction mixtures were subjected to SDS-PAGE followed by staining with Ponceau S or by immunoblot analysis with antibodies to phosphotyrosine Together, these observations indicated that xCT and GluN2B play key roles in the malignant behavior of glioma in vivo and that both system xc(-) and NMDAR are, therefore, promising targets for cancer therapy, especially for the treatment of EGFR-overexpressing glioma. RT-PCR analysis of xCT and GluN2B mRNA abundance in U87MG-E cells stably expressing control, xCT or GluN2B shRNA (n = 4 independent experiments). C, Kaplan-Meier survival curves for mice with brain tumors derived from implanted U87MG-E cells stably expressing control, xCT or GluN2B shRNA(n = 4 for each group). Data in (A) to (C) are means ± SEM. *P < .05, ** P < .01, ***P < .001 (1-way ANOVA followed by Tukey's post hoc test [A and B] or the log-rank test [C]). D, Model for the interaction between epidermal growth factor receptor (EGFR)-overexpressing glioma cells and free amino acids mediated by system xc(-) and NMDAR. EGFR constitutively interacts with the xCT subunit of cystine-glutamate antiporter system xc(-) in a kinase-independent manner and thereby promotes the cell surface expression of xCT and increases both the uptake of extracellular cystine and the release of intracellular glutamate. The increased cystine uptake boosts cellular defense against reactive oxygen species (ROS) and thereby promotes resistance to oxidative stress through promotion of reduced glutathione (GSH) synthesis. Activated EGFR mediates phosphorylation of the COOH-terminal region of GluN2B, resulting in enhancement of glutamate-NMDAR signaling and consequent promotion of glioma cell invasion invasive phenotype of EGFR-overexpressing glioma cells. Together with our previous observation that EGFR activates system xc(-) in glioma cells, 8 our present results establish a role for EGFR expression in the generation of a glutamate-rich microenvironment and consequent promotion of glioma cell migration through activation of NMDAR signaling.
| D ISCUSS I ON
N-methyl-d-aspartate-sensitive glutamate receptors are heterotetramers that contain 2 GluN1 glycine-binding subunits and 2 GluN2 (GluN2A to GluN2D) or GluN3 (GluN3A and GluN3B)
glutamate-binding subunits. 27, 28 Src family kinases have been shown to enhance NMDAR activity in neurons through tyrosine phosphorylation of the COOH-terminal domain of GluN2A and GluN2B subunits. [29] [30] [31] The COOH-terminal domain of these GluN2
subunits contains an internalization motif, the tyrosine phosphorylation of which inhibits binding of the clathrin adapter AP-2 and thereby promotes cell surface expression of NMDAR. 32, 33 In the present study, we found that EGFR constitutively interacts with 
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